EMPOWER-Lung 1: Baseline Characteristics and Modern Treatment Considerations in NSCLC

EP: 1.Setting the Stage: Immunotherapy’s Impact and EMPOWER-Lung 1 Study Design

EP: 2.Optimizing First-Line and Sequential Therapy in Advanced NSCLC

Now Viewing

EP: 3.EMPOWER-Lung 1: Baseline Characteristics and Modern Treatment Considerations in NSCLC

EP: 4.Evaluating Five-Year Efficacy Outcomes in EMPOWER-LUNG 1

EP: 5.Subgroup Analyses of EMPOWER-LUNG 1

EP: 6.Managing Safety and Quality of Life With Cemiplimab in Advanced NSCLC

EP: 7.The Role of Continuing Cemiplimab in Second-Line Therapy After Progression

EP: 8.Closing Insights: The Future of Cemiplimab in NSCLC and Beyond

EP: 9.Evaluating Five-year Efficacy Outcomes in the EMPOWER-Lung 1 Study | Written Recap

Video content above is prompted by the following:

• How does histology, staging and ECOG performance status play into treatment considerations at your practice today, and how do these factors compare to the baseline characteristics of this study?
• What other biomarkers, if any, are important in determining the efficacy of PD-1 inhibitors like cemiplimab before initiating therapy, both in NSCLC and for other indications?
• Overall, how does this patient population compare with those treated in 2025 with immune checkpoint inhibitors or other first-line treatment options for advanced NSCLC?